Added Value of Three-dimensional Transvaginal Ultrasound (3D TVUS) and Gel Infusion Sonography (3D GIS) Compared With Magnetic Resonance Imaging (MRI) in the Diagnosis of Patients With Suspicion of a Uterine Septum.

NCT ID: NCT07263984

Last Updated: 2025-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

145 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-27

Study Completion Date

2028-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to investigate the added value of three-dimensional transvaginal ultrasound (3D TVUS) and gel infusion sonography (3D GIS) for diagnosing a partition in the uterus (uterine septum) in comparison to magnetic resonance imaging (MRI). The main question it aims to answer is:

How well do 3D TVUS and 3D GIS detect a uterine septum compared to MRI?

Participants will receive 3D TVUS/ 3D GIS and MRI, and will complete questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Septum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Central readers of US and MRI images

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with suspicion of a uterine septum on two-dimensional transvaginal ultrasound

Patients with suspicion of a uterine septum on two-dimensional transvaginal ultrasound

Group Type EXPERIMENTAL

Magnetic Resonance Imaging

Intervention Type DIAGNOSTIC_TEST

MRI of the pelvis

Three-dimensional transvaginal ultrasound

Intervention Type DIAGNOSTIC_TEST

Three-dimensional transvaginal ultrasound

Three-dimensional transvaginal Gel Infusion Sonography

Intervention Type DIAGNOSTIC_TEST

Three-dimensional transvaginal Gel Infusion Sonography

Questionnaires

Intervention Type OTHER

Questionnaires

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic Resonance Imaging

MRI of the pelvis

Intervention Type DIAGNOSTIC_TEST

Three-dimensional transvaginal ultrasound

Three-dimensional transvaginal ultrasound

Intervention Type DIAGNOSTIC_TEST

Three-dimensional transvaginal Gel Infusion Sonography

Three-dimensional transvaginal Gel Infusion Sonography

Intervention Type DIAGNOSTIC_TEST

Questionnaires

Questionnaires

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged between 18 and 45 years
* With suspicion of a uterine septum on routine 2D TVUS
* Who are willing to give informed consent

Exclusion Criteria

* Women aged below 18 years and over 45 years
* Prior definitive diagnosis of a uterine septum or other congenital uterine anomaly
* Prior surgery in relation to a uterine septum
* Cervical (unilateral) aplasia
* Vaginal aplasia
* Untreated obstructive vaginal septum
* Any co-morbidity that is found to interfere with the uterine measurements required in the study
* Contraindications for MRI
* Not willing or not possible to undergo transvaginal ultrasound
* Pregnancy at the time of inclusion
* Wish to conceive between inclusion and last diagnostic intervention
* Visual or pathological evidence of cervical, uterine or ovarian malignancy
* Patients with an intrauterine device (by mistake), who are not willing to remove this device before the start of the diagnostic interventions
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek)

OTHER

Sponsor Role collaborator

University Hospital, Ghent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ghent University Hospital

Ghent, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laura D'hoore, MD

Role: CONTACT

0032 9 332 07 58

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Laura D'hoore, MD

Role: primary

0032 9 332 07 58

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

T002825N

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

ONZ-2025-0219

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

OB-GYN Clinical Validation Study
NCT06449872 COMPLETED NA